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paring adherent patients (1-CMG ≥ 80%) to non-
adherent patients (<80%), mean ± SD levels of HbA1c,
LDL, and BP were lower in the adherent than in the non-
adherent group: 8.0 ± 1.2 vs. 8.5 ± 1.4% for HbA1c 
(p < 0.01), 103.2 ± 28.1 vs. 123.3 ± 34.2mg/dL for LDL
(p < 0.01); and 137.8 ± 12.4 vs. 142.9 ± 12.9mmHg for
SBP (p < 0.01). Adjustment for socio-demographic char-
acteristics did not attenuate the strength of the associa-
tions. CONCLUSIONS: Adherence measured by claims
data correlated with clinical outcomes in DM2 patients.
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OBJECTIVE: To evaluate the impact of a population-
based, diabetes intervention program on patient self-
management behaviors and health system screening 
practices and risk factor management. METHODS:
A population-based diabetes intervention program was
developed by a large, regional managed care plan in the
northern Midwest and a health management subsidiary
of a pharmaceutical company. Program interventions
included periodic education mailings, brochures, newslet-
ters and kits, as well as telephonic case management for
high-risk patients. Six hundred thirty-eight diabetic
members of the health plan completed surveys before and
after one year of program participation, with a 48%
response rate. A second cohort of 956 diabetic patients
that did not participate in the interventions served as a
control group. The evaluation of program impact was
examined using two quasi-experimental designs: 1) one-
group pretest-posttest, and 2) a posttest only design with
nonequivalent groups. Information solicited in the survey
included quality of life issues, frequency of monitoring
activities, behavioral risk factor management, and inter-
mediate clinical outcomes (i.e., HbA1c values, blood pres-
sure, blood glucose levels). RESULTS: Mean quality of
life scores (PAID) improved signiﬁcantly from baseline in
the intervention group (P < 0.01) and were signiﬁcantly
higher than controls (P < 0.01). Statistical improvements
(P < 0.01)were noted from baseline for blood glucose
monitoring. At follow-up, signiﬁcantly more patients in
Cohort 1 reported pre-meal blood glucose levels of <140
(P < 0.01) and mean decreases in low and high blood
sugar episodes. Clinical screening exams were almost all
signiﬁcantly improved in the intervention group com-
pared with controls. With the exception of smoking,
which showed a signiﬁcant decrease in the intervention
group, health behaviors such as following a meal plan
and exercising were not affected. There were no changes
reported in body mass index (BMI). CONCLUSIONS:
A population-based intervention program implemented
within a large health plan produced measurable improve-
ments in diabetes-related behaviors and outcomes.
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OBJECTIVES: Assessing risk proﬁles and medical opti-
misation potentials (MOP) for diabetics participating 
in a German diabetes management (DM) project.
METHODS: Medical record data from privately insured
type-2 diabetics participating in a DM project were used
to calculate individual 10-year-probabilities of com-
plications with a Markov-chain based disease model
(Mellibase). MOPs are the relative risk difference when
comparing present individual risk versus risk of a patient
achieving national guideline values for key risk factors
(HbA1c, systolic blood pressure (SBP), total cholesterol,
HDL cholesterol, triglycerides, smoking status). MOPs
were communicated to patients and their physicians using
Mellibase reports. Assessments are repeated after 3 and
6 months. RESULTS: Of 178 type-2 diabetics (mean 
age 58 years, diabetes diagnosed since median 7 years,
8% females) 97/85% had at least one risk factor at
medium/high level according to guideline. A total of
15/29/28/28% of the diabetics shows 0/1/2/≥3 risk factors
at a high level. A total of 43% of participants exhibit a
MOP for retinopathy of at least 40%. MOPs for myocar-
dial infarction, stroke, foot amputation and renal failure
were 25/15/25/17%. For each 100 DIAMART diabetics
with 1/2/≥3 risk factors at high level the MOPs are equiv-
alent to 5/11/23 less expected events over 10 years,
reﬂecting the enormous opportunity for improvement.
First 3 months follow-up data (80 diabetics) indicate sig-
niﬁcant reductions for HbA1c, SBP, and total cholesterol
among high risk patients. CONCLUSIONS: Diabetics
participating in DIAMART at the start are at high risk
for complications, resulting in substantial MOP. First
follow-up data suggest that MOPs, when used by the
physician via Mellibase reports to inform and motivate
the patient, could be an effective tool to motivate for
reaching recommended guideline risk levels by translat-
ing risk into opportunities. For DM planning MOPs
quantify potential beneﬁts from speciﬁc interventions
(e.g. anti-smoking initiative) in diabetes care and help
focusing efforts on improving outcomes.
